drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A humanized, afucosylated IgG1 monoclonal antibody (brand: Fasenra) that targets IL-5 receptor alpha (IL-5Rα) on eosinophils and basophils, blocks IL-5 signaling, and engages FcγRIIIa on NK cells to drive ADCC-mediated depletion of these cells; administered subcutaneously (e.g., 30 mg/10 mg) for eosinophilic asthma.
nci_thesaurus_concept_id
C88594
nci_thesaurus_preferred_term
Benralizumab
nci_thesaurus_definition
An afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra), with potential anti-asthmatic activity. Upon administration, benralizumab binds to IL-5Ra and elicits an antibody-directed cell cytotoxicity (ADCC) against IL-5Ra-expressing cells. This induces apoptosis in IL-5Ra-expressing cells and may reduce asthmatic episodes. IL-5Ra, expressed on both eosinophils and basophils, plays a key role in asthma.
drug_mesh_term
Benralizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Benralizumab is an afucosylated humanized IgG1 monoclonal antibody that binds IL-5 receptor alpha on eosinophils and basophils, blocks IL-5 signaling, and engages FcγRIIIa on NK cells to trigger ADCC-mediated depletion of these cells, reducing eosinophilic inflammation.
drug_name
Benralizumab
nct_id_drug_ref
NCT06427876